Budesonide / formoterol (Symbicort)
What studies of Budesonide / formoterol (Symbicort) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 2 findings, all C.
2 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Budesonide / formoterol (Symbicort) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Budesonide / formoterol (Symbicort) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Breathlessness1 study · 2 (few people) people used Budesonide / formoterol (Symbicort) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (2 in all); not all results were tested against chance.
Studies with no comparison group10 in the study · variable per patient (Table 1 · 24 mcg/day
Breathlessness improved.
The evidence is very uncertain about the effect of Budesonide / formoterol (Symbicort) on breathlessness in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (2 in all)
- Not all results were tested against chance
See the 1 study
-
Insights in the Management of Long COVID-19: Preliminary Observations (2022)
- People in the study
- 10 in the study
- Dose
- 24 mcg/day
- Outcome
- mMRC dyspnoea scores modified Medical Research Council
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Daily functioning1 study · 2 (few people) people used Budesonide / formoterol (Symbicort) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (2 in all); not all results were tested against chance.
Studies with no comparison group10 in the study · variable per patient (Table 1 · 24 mcg/day
Daily functioning improved.
The evidence is very uncertain about the effect of Budesonide / formoterol (Symbicort) on daily functioning in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (2 in all)
- Not all results were tested against chance
See the 1 study
-
Insights in the Management of Long COVID-19: Preliminary Observations (2022)
- People in the study
- 10 in the study
- Dose
- 24 mcg/day
- Outcome
- walk distance on 6MWT Six-Minute Walk Test
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Side effects
No study of this treatment alone reported side effects we could read.
All papers
- Clinical characteristics and effects of inhaled corticosteroid in patients with post-COVID-19 chronic cough during the Omicron variant outbreak.2024 · compared with another group · 104 in the study
Summary
An ambispective, longitudinal cohort study enrolled 104 patients with post-COVID-19 chronic cough at a respiratory clinic between January 1, 2023, and March 31, 2023. Patients received conventional symptomatic cough suppressants and/or expectorants; 51 also received budesonide/formoterol powder for inhalation 2 puffs per day (ICS group), and 53 did not receive ICS (NICS group). Follow-up was at 30 and 60 days. At 60 days, recovery was reported in 31 (60.8%) ICS patients versus 36 (67.9%) NICS patients (p = 0.447); improved symptoms in 18 (35.3%) versus 14 (26.4%) (p = 0.327); not improved in 2 (3.9%) versus 3 (5.7%) (p = 1.000). CET change from baseline was not significantly different between groups at day 30 (p = 0.178) or day 60 (p = 0.094). Dyspnea scale scores between groups at each visit and the median change to day 60 were comparable (all p > 0.05). A second examination was performed in 67 patients (35 ICS, 32 NICS). FEV1% change was 3.9 versus 1.7 (p = 0.007), FEV1/FVC change 1.6 versus 0.8 (p = 0.001), MMEF% change 9.8 versus 2.2 (p = 0.000), MVV% change 10.7 versus 3.5 (p = 0.013), and FeNO50 change −3.0 versus −1.0 (p = 0.041). Overall, 99/104 improved at 60 days. Harms were not systematically described; the authors reported that "a very small number of patients showed no improvement or even deterioration of lung function"; withdrawals for harms were not reported. Limitations included single-center small sample, no non-COVID chronic cough control, and possible spontaneous remission.
- Insights in the Management of Long COVID-19: Preliminary Observations2022 · no comparison group · 10 in the study
Summary
This retrospective analysis included 10 patients with long COVID pulmonary sequelae seen at one unit of the outpatient department of Viswanathan Chest Hospital between June 2020 and December 2020. Inclusion required no pre-existing pulmonary disease and available follow-up visits. Five LC-ILD patients with resting hypoxia or exertional desaturation were prescribed systemic steroids (oral deflazacort) plus oral acebrophylline and supplemental oxygen; 2 other LC-ILD patients were prescribed oral acebrophylline only; 2 LC-OAD patients received inhaled budesonide plus inhaled formoterol, with a 7 days course of oral deflazacort; 1 long COVID cough patient received oral acebrophylline. Treatment duration was variable per patient (Table 1). Outcomes included clinical, radiological and functional improvement, resting hypoxia and exertional desaturation, 6MWT distance, mMRC dyspnoea scores, and chest radiograph/HRCT findings. The paper reports improvement in the treated groups: LC-ILD patients responded to oral steroid therapy and showed clinical, radiological as well as functional improvement; LC-OAD patients responded well to inhaled corticosteroids and bronchodilators with symptomatic and functional improvement. Follow-up durations were recorded per patient. The study had no comparison group. Harms and withdrawals were not reported.
- Small airway disease in post-acute COVID-19 syndrome, a non-conventional approach in three years follow-up of a patient with long COVID: a case report.2023 · combination: given with other treatments · 1 in the study
Summary
This case report described one 60-year-old Hispanic patient who developed severe COVID-19 pneumonia in April 2020, treated at home because the healthcare system was oversaturated, and later had post-acute COVID-19 syndrome. After persistent dyspnea and fatigue, the patient began a bronchodilator twice daily for nine months with low-dose inhaled corticosteroids (160 µg of budesonide and 4.5 µg of formoterol fumarate dihydrate); pulmonary rehabilitation was reinstated. Earlier treatment also included corticosteroids, oxygen via a nasal cannula, and pulmonary rehabilitation. There was no comparison group; outcomes were within-patient before/after measures. At 36 months, restrictive parameters remained stable and DLCO normalized; 6MWT performance was 87% but significant desaturation persisted. CT showed reduced GGO and air trapping, while traction bronchiectasis persisted. FOT and MBW scores improved without normalization. The report also states that oscillometric and MBW measurements improved after a year of follow-up. Side effects and withdrawals were not reported. The authors state that more studies are needed.